<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Proc Natl Acad Sci U S A</journal-id>
<journal-id journal-id-type="iso-abbrev">Proc. Natl. Acad. Sci. U.S.A</journal-id>
<journal-id journal-id-type="hwp">pnas</journal-id>
<journal-id journal-id-type="pmc">pnas</journal-id>
<journal-id journal-id-type="publisher-id">PNAS</journal-id>
<journal-title-group>
<journal-title>Proceedings of the National Academy of Sciences of the United States of America</journal-title>
</journal-title-group>
<issn pub-type="ppub">0027-8424</issn>
<issn pub-type="epub">1091-6490</issn>
<publisher>
<publisher-name>National Academy of Sciences</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29844171</article-id>
<article-id pub-id-type="pmc">6004444</article-id>
<article-id pub-id-type="publisher-id">201800077</article-id>
<article-id pub-id-type="doi">10.1073/pnas.1800077115</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>PNAS Plus</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Biological Sciences</subject>
<subj-group>
<subject>Biophysics and Computational Biology</subject>
</subj-group>
</subj-group>
<series-title>PNAS Plus</series-title>
</article-categories>
<title-group>
<article-title>Dynamic action potential clamp predicts functional separation in mild familial and severe de novo forms of <italic>SCN2A</italic> epilepsy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Berecki</surname>
<given-names>Géza</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="corresp" rid="cor1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Howell</surname>
<given-names>Katherine B.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>b</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>c</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>d</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Deerasooriya</surname>
<given-names>Yadeesha H.</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>e</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cilio</surname>
<given-names>Maria Roberta</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>f</sup>
</xref>
<xref ref-type="aff" rid="aff7">
<sup>g</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Oliva</surname>
<given-names>Megan K.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kaplan</surname>
<given-names>David</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Scheffer</surname>
<given-names>Ingrid E.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>b</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>c</sup>
</xref>
<xref ref-type="aff" rid="aff8">
<sup>h</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0003-4580-841X</contrib-id>
<name>
<surname>Berkovic</surname>
<given-names>Samuel F.</given-names>
</name>
<xref ref-type="aff" rid="aff8">
<sup>h</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Petrou</surname>
<given-names>Steven</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="aff" rid="aff9">
<sup>i</sup>
</xref>
<xref ref-type="aff" rid="aff10">
<sup>j</sup>
</xref>
<xref ref-type="aff" rid="aff11">
<sup>k</sup>
</xref>
<xref ref-type="corresp" rid="cor1">
<sup>1</sup>
</xref>
</contrib>
<aff id="aff1"><sup>a</sup>Ion Channels and Disease Group, The Florey Institute of Neuroscience and Mental Health, <institution>University of Melbourne</institution>, Parkville, VIC 3052, <country>Australia</country>;</aff>
<aff id="aff2"><sup>b</sup>Department of Neurology, <institution>Royal Children’s Hospital</institution>, Parkville, VIC 3052, <country>Australia</country>;</aff>
<aff id="aff3"><sup>c</sup>Department of Pediatrics, <institution>University of Melbourne</institution>, Parkville, VIC 3052, <country>Australia</country>;</aff>
<aff id="aff4"><sup>d</sup><institution>Murdoch Children’s Research Institute</institution>, Parkville, VIC 3052, <country>Australia</country>;</aff>
<aff id="aff5"><sup>e</sup>Department of Mechanical Engineering, <institution>University of Melbourne</institution>, Parkville, VIC 3052, <country>Australia</country>;</aff>
<aff id="aff6"><sup>f</sup>Department of Neurology, University of California, San Francisco Benioff Children’s Hospital, <institution>University of California, San Francisco</institution>, <addr-line>CA</addr-line> 94158;</aff>
<aff id="aff7"><sup>g</sup>Department of Pediatrics, University of California, San Francisco Benioff Children’s Hospital, <institution>University of California, San Francisco</institution>, <addr-line>CA</addr-line> 94158;</aff>
<aff id="aff8"><sup>h</sup>Epilepsy Research Centre, Department of Medicine, <institution>University of Melbourne</institution>, Austin Health, Heidelberg, VIC 3084, <country>Australia</country>;</aff>
<aff id="aff9"><sup>i</sup>Department of Medicine, Royal Melbourne Hospital, <institution>University of Melbourne</institution>, Parkville, VIC 3050, <country>Australia</country>;</aff>
<aff id="aff10"><sup>j</sup>Australian Research Council (ARC) Centre of Excellence for Integrated Brain Function, <institution>University of Melbourne</institution>, Parkville, VIC 3052, <country>Australia</country>;</aff>
<aff id="aff11"><sup>k</sup><institution>RogCon, Inc.</institution>, Cambridge, <addr-line>MA</addr-line> 02142</aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><sup>1</sup>To whom correspondence may be addressed. Email: <email>geza.berecki@florey.edu.au</email> or <email>steve.petrou@unimelb.edu.au</email>.</corresp>
<fn fn-type="edited-by">
<p>Edited by Bruce P. Bean, Harvard Medical School, Boston, MA, and approved May 9, 2018 (received for review January 3, 2018)</p>
</fn>
<fn fn-type="con">
<p>Author contributions: G.B. and S.P. designed research; G.B. performed research; Y.H.D., M.K.O., D.K., S.F.B., and S.P. contributed new reagents/analytic tools; G.B., K.B.H., Y.H.D., M.R.C., and I.E.S. analyzed data; G.B., K.B.H., and S.P. wrote the paper; K.B.H., M.R.C., and I.E.S. collected and summarized electro-clinical data; and Y.H.D. contributed to the editing of the paper.</p>
</fn>
<fn fn-type="COI-statement">
<p>Conflict of interest statement: G.B. is funded by RogCon, Inc., Miami, Florida, a biotechnology company focused on drug research, discovery, and development for select ion channelopathies, including SCN2A. I.E.S. has served on scientific advisory boards for UCB, Eisai, GlaxoSmithKline, Biomarin, and Nutricia; editorial boards of the <italic>Annals of Neurology</italic>, <italic>Neurology and Epileptic Disorders</italic>; may accrue future revenue on pending patent WO61/010176 (filed: 2008): Therapeutic Compound; has received speaker honoraria from GlaxoSmithKline, Athena Diagnostics, UCB, Eisai, and Transgenomics; has received funding for travel from Athena Diagnostics, UCB, Biocodex, GlaxoSmithKline, Biomarin, and Eisai; and receives/has received research support from the National Health and Medical Research Council of Australia, National Institutes of Health, Australian Research Council, Health Research Council of New Zealand, CURE, The American Epilepsy Society, the US Department of Defense Autism Spectrum Disorder Research Program, March of Dimes, and Perpetual Charitable Trustees. S.P. is cofounder, Chief Scientific Officer, and equity holder of RogCon, Inc., Miami, Florida, a biotech company focused on the delivery of novel therapeutics for SCN2A disorders. RogCon, Inc. provided funding for this project. S.P. is also cofounder and equity holder in Praxis Precision Medicines, Inc., Cambridge, Massachusetts, which develops precision medicines for neurogenetic disorders, including those caused by SCN2A mutations. S.P. is a Scientific Advisor and equity holder in Pairnomix, Inc., Minneaopolis, Minnisota, which is undertaking precision medicine development in epilepsy and related disorders.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>12</day>
<month>6</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>29</day>
<month>5</month>
<year>2018</year>
</pub-date>
<volume>115</volume>
<issue>24</issue>
<fpage>E5516</fpage>
<lpage>E5525</lpage>
<permissions>
<copyright-year>2018</copyright-year>
<license>
<ali:license_ref specific-use="vor" xmlns:ali="http://www.niso.org/schemas/ali/1.0/"></ali:license_ref>
<license-p>Published under the <ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/site/aboutpnas/licenses.xhtml">PNAS license</ext-link>.</license-p>
</license>
</permissions>
<self-uri xlink:href="pnas.201800077.pdf" xlink:title="pdf"></self-uri>
<abstract abstract-type="executive-summary">
<title>Significance</title>
<p><italic>SCN2A</italic>, encoding the voltage-gated sodium channel Na<sub>v</sub>1.2, has emerged as a major gene implicated in neonatal-, infantile-, and even childhood-onset epilepsies. Many of these epilepsies are also associated with cognitive and behavioral impairments that range in type and severity. The biophysical, neurophysiological, and clinical impacts of <italic>SCN2A</italic> mutations are poorly understood. Here, we use clinical evaluation and biophysical analyses to explore the mechanisms underpinning distinctive phenotypes produced by <italic>SCN2A</italic> variants associated with mild familial or severe de novo forms of epilepsy. We show that dynamic clamp analysis provides clear benefits over conventional voltage clamp for a rapid and definitive prediction of neuron-scale phenotypic consequences, and is well positioned to impact diagnosis and drug discovery in genetic epilepsy.</p>
</abstract>
<abstract>
<p>De novo variants in <italic>SCN2A</italic> developmental and epileptic encephalopathy (DEE) show distinctive genotype–phenotype correlations. The two most recurrent <italic>SCN2A</italic> variants in DEE, R1882Q and R853Q, are associated with different ages and seizure types at onset. R1882Q presents on day 1 of life with focal seizures, while infantile spasms is the dominant seizure type seen in R853Q cases, presenting at a median age of 8 months. Voltage clamp, which characterizes the functional properties of ion channels, predicted gain-of-function for R1882Q and loss-of-function for R853Q. Dynamic action potential clamp, that we implement here as a method for modeling neurophysiological consequences of a given epilepsy variant, predicted that the R1882Q variant would cause a dramatic increase in firing, whereas the R853Q variant would cause a marked reduction in action potential firing. Dynamic clamp was also able to functionally separate the L1563V variant, seen in benign familial neonatal–infantile seizures from R1882Q, seen in DEE, suggesting a diagnostic potential for this type of analysis. Overall, the study shows a strong correlation between clinical phenotype, <italic>SCN2A</italic> genotype, and functional modeling. Dynamic clamp is well positioned to impact our understanding of pathomechanisms and for development of disease mechanism-targeted therapies in genetic epilepsy.</p>
</abstract>
<kwd-group>
<kwd>de novo SCN2A mutation</kwd>
<kwd>dynamic action potential clamp</kwd>
<kwd>epilepsy</kwd>
<kwd>voltage clamp</kwd>
<kwd>modeling</kwd>
</kwd-group>
<funding-group>
<award-group id="gs1">
<funding-source id="sp1">RogCon, Inc.</funding-source>
<award-id rid="sp1">n/a</award-id>
<principal-award-recipient>Geza Berecki</principal-award-recipient>
<principal-award-recipient>Katherine B Howell</principal-award-recipient>
<principal-award-recipient>Steven Petrou</principal-award-recipient>
</award-group>
<award-group id="gs2">
<funding-source id="sp2">ARC Centre of Excellence for Integrative Brain Research</funding-source>
<award-id rid="sp2">CE14010007</award-id>
<principal-award-recipient>Geza Berecki</principal-award-recipient>
<principal-award-recipient>Katherine B Howell</principal-award-recipient>
<principal-award-recipient>Steven Petrou</principal-award-recipient>
</award-group>
<award-group id="gs3">
<funding-source id="sp3">Department of Health | National Health and Medical Research Council (NHMRC)<named-content content-type="funder-id">501100000925</named-content></funding-source>
<award-id rid="sp3">10915693</award-id>
<principal-award-recipient>Steven Petrou</principal-award-recipient>
</award-group>
<award-group id="gs4">
<funding-source id="sp4">NHMRC Fellowship</funding-source>
<award-id rid="sp4">GNT1005050</award-id>
<principal-award-recipient>Geza Berecki</principal-award-recipient>
<principal-award-recipient>Katherine B Howell</principal-award-recipient>
<principal-award-recipient>Steven Petrou</principal-award-recipient>
</award-group>
<award-group id="gs5">
<funding-source id="sp5">Clinician-Scientis Fellowship</funding-source>
<award-id rid="sp5">n/a</award-id>
<principal-award-recipient>Geza Berecki</principal-award-recipient>
<principal-award-recipient>Katherine B Howell</principal-award-recipient>
<principal-award-recipient>Steven Petrou</principal-award-recipient>
</award-group>
</funding-group>
<counts>
<page-count count="10"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>